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ABSTRACT
In the adult organism, angiogenesis is restricted to a few physiological conditions. On the other hand, uncontrolled 
angiogenesis have often been associated to angiogenesis-dependent pathologies. A variety of animal models 
have been described to provide more quantitative analysis of in vivo angiogenesis and to characterize pro- and 
antiangiogenic molecules. However, it is still necessary to establish a quantitative, reproducible and specific 
method for studies of angiogenesis factors and inhibitors. This work aimed to standardize a method for the 
study of angiogenesis and to investigate the effects of thalidomide on angiogenesis. Sponges of 0.5 x 0.5 x 
0.5 cm were implanted in the back of mice groups, control and experimental (thalidomide 200 mg/K/day by 
gavage). After seven days, the sponges were removed. The dosage of hemoglobin in sponge and in circulation 
was performed and the ratio between the values was tested using nonparametric Mann-Whitney test. Results 
have shown that sponge-induced angiogenesis quantitated by ratio between hemoglobin content in serum and 
in sponge is a helpful model for in vivo studies on angiogenesis. Moreover, it was observed that sponge-induced 
angiogenesis can be suppressed by thalidomide, corroborating to the validity of the standardized method.
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INTRODUCTION
Angiogenesis, the formation and growth of 
new capillary blood vessels, is normally under 
stringent control. Expansion of the capillary bed 
by angiogenesis is in the healthy adult limited to 
wound healing, physiological growth of tissues 
(e.g. fat, skeletal muscle) and cyclic variations in 
the endometrium and the corpus luteum (Hori et 
al. 1996, Andrade et al. 1997, Kilarski et al. 2012). 
By contrast, uncontrolled angiogenesis can often 
been seen as a contributing factor in a number of 
angiogenesis-dependent pathologies, such as tumor 
growth, proliferative retinopathies, rheumatoid 
arthritis and psoriasis (Kilarski et al. 2012).
Stimuli such as carbon dioxide, nitric oxide, 
hypoxia or the increased metabolic demands 
associated with exercise work through multiple 
pathways regulate angiogenesis in a complex 
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process mediated by a number of growth factors 
and cytokines, such as vascular endothelium 
growth factors (VEGF), fibroblast growth factors 
(FGF), angiopoietin, platelet-derived growth 
factors (PDGF), tumor necrosis factor-α, and 
some interleukins. Elucidating exactly how 
angiogenic pathways are integrated in different 
pathophysiological contexts will be of great interest 
(Poon et al. 2001, Wang et al. 2005, Lahteenvuo 
and Rosenzweig 2012, Claesson-Welsh 2012).
Recent studies have shown that angiogenesis 
inhibitors are promising therapies for the treatment 
of patients with cancer. Most of antiangiogenic 
drugs block the formation of growth factors such 
as VEGF and others. Different approaches have 
been explored such as VEGF traps and inhibitors 
of VEGF kinase activity, anti-VEGF receptor 
antibodies and more recently drugs that target 
additional factors such as FGF, platelet-derived 
growth factors and others antiangiogenic drugs 
(Fokas et al. 2012). For example, Bevacizumab 
is a recombinant, humanized, monoclonal 
immunoglobulin G1 antibody targeted at VEGF-A 
that was approved by the United State`s Food and 
Drug Administration (FDA) for the treatment of 
metastatic colorectal cancer, non-squamous non-
small cell lung cancer, glioblastoma, and metastatic 
renal cell carcinoma. This antibody binds to and 
neutralizes all biologically active forms of VEGF-A 
(e.g. VEGF-A165) which suppresses growth of 
tumors and inhibits progression of metastatic 
disease (Itamochi and Kigawa 2012).
Thalidomide (α-N-phthalimido glutarimide) 
is a glutamic acid derivative that was first 
introduced in 1954 as a sedative drug but was 
withdrawn from the market due to its teratogenic 
effects. Thalidomide has various pharmacological 
properties such as immunomodulatory, anti-
inflammatory and antiangiogenic activity and it has 
been used successfully for various inflammatory 
and autoimmune diseases and some tumors 
(Amirshahrokhi and Ghazi-Khansari 2012).
A variety of animal models have been 
described to provide more quantitative analysis of 
in vivo angiogenesis and to characterize pro- and 
antiangiogenic molecules (Andrade et al. 1997). 
The assays for angiogenesis that are frequently used 
include the chick chorioallantoic membrane (CAM), 
transparent chambers, matrix or sponge implants 
and the cornea model. All utilize the pre-existing 
vasculature as a source of vessels that expand into 
an implanted or injury-induced matrix. However, 
none of these methods and their modifications are 
ideal as they are difficult to quantify or observe 
vascular growth continuously. It is necessary to 
establish a quantitative, reproducible and specific 
method for studies of angiogenesis factors and 
inhibitors (Andrade et al. 1987).
The present study aimed to evaluate and 
quantify the angiogenic potential of thalidomide, 
by in vivo mice sponge implantation assay. This 
method was chosen to be standardized as it was 
reproducible, not dependent on the observer's 
experience, and could be applied in the Faculdade 
de Medicina do ABC (Andrade et al. 1997, Ferreira 
et al. 2004, Schönherr et al. 2004).
OBJECTIVES
1) To standardize a method for the study of 
angiogenesis.
2) To investigate the effects of thalidomide on 
angiogenesis.
MATERIALS AND METHODS
Animals from the Faculdade de Medicina do 
ABC were used. Throughout the experiment, all 
animals were maintained on a 12:12-h light-dark 
cycle, under controlled temperature and humidity 
conditions and with free access to food and water. 
The experimental protocol was approved by the 
Ethical Committee for Animal Experimentation 
(EAEC). Efforts were made to minimize animal 
suffering and to reduce the number of animals used.
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SPONGE IMPLANTATION
Sponges (0.5 x 0.5 x 0.5 cm) were aseptically im-
planted subcutaneously on the back of Balb/c mice 
(n = 14) under general anesthesia with ketamine (100 
mg/kg) and xylazine (10 mg/kg), intraperitoneally.
THALIDOMIDE TREATMENT
Animals were randomly divided into two groups:
a) Control group - 7 animals received by gavage a 
single daily dose of 0.2 mL of milk for a week.
b) Experimental group - 7 animals were treated 
with a single daily dose of thalidomide (200 mg/
kg) diluted in milk, since the drug is not soluble 
in water, by gavage for a week.
Animals were monitored daily.
EVALUATION OF ANGIOGENESIS
After seven days, the mice were anesthetized 
as previously described. A blood sample from 
circulation was obtained in order to compare both 
hemoglobin values from serum and sponge. The 
sponges were carefully removed and the contents 
were homogenized in 2.0 mL of saline and centrifuged 
at 10,000 x g for 15 minutes. The supernatant was 
filtered through a 0.22 micron filter (Millipore).
Hemoglobin concentration was determined 
spectrophotometrically at 540 nm by using the 
hemoglobin assay kit (Sigma Drabkin´s reagent).
STATISTICAL ANALySIS
Hemoglobin content in sponge and in serum 
was tested using nonparametric Mann-Whitney 
test. GBstat 9.0 software was used. p < 0.05 was 
considered statistically significant.
RESULTS
Table I shows ratio between hemoglobin values 
obtained in sponge and in serum. It is possible to 












Mean+/- SD 0.77+/-0.18 0.56+/-0.22*
TABLE I
Ratio between hemoglobin content in sponge and serum.
*p ≤ 0.05
DISCUSSION
A number of pro- and antiangiogenic molecules 
have entered clinical trials for a variety of diseases. 
However, in spite of promising results obtained 
from animal models, many therapies have failed 
when applied in the clinic. These discrepancies 
suggest that current in vivo angiogenesis assays 
should be improved in order to better understand 
mechanisms nondevelopmental angiogenesesis 
during tissue vascularization and repair (Kilarski 
et al. 2012). Moreover, one of the difficulties of 
current methods of measuring angiogenesis is the 
assessment of vascularization which is usually to 
subjective to be reproducible between laboratories 
and even between individuals (Andrade et al. 1987).
This paper describes a quantitative method for 
the study of angiogenesis in mice. It was adapted 
from Andrade et al. (1987, 1997) and it offers 
several advantages: (i) an objective assessment 
of angiogenesis; (ii) reproducibility and (iii) 
evaluation of angiogenesis by comparison between 
hemoglobin content in serum and in sponge.
We have shown that the sponge-induced 
angiogenesis can be suppressed by thalidomide. 
Thalidomide is listed as a drug that potentially 
would target multiple components of tumor 
microenvironment (angiogenesis, inflammation, 
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proliferative activity). Despite these well-
characterized effects and a large number of 
publications, the results of the effects of thalidomide 
on a number of clinical and experimental protocols 
are rather contradictory and/or inconsistent (Souza 
et al. 2012).
Thalidomide was approved by the FDA for 
the treatment of erythema nodosum leprosum 
(ENL) and multiple myeloma. It has also been 
demonstrated that thalidomide or its analogs are 
effective in the treatment of rheumatoid arthritis, 
Crohn’s disease, prostate cancer, Behcet’s 
disease, chronic host-versus-graft disease, lupus 
erythematosis and HIV-associated oral ulcers. 
However, teratogenicity, peripheral neuropathy 
and other adverse effects of thalidomide have led 
to the design of its new analogs with low toxicity 
(Amirshahrokhi and Ghazi-Khansari 2012).
The mechanism of thalidomide action is not 
yet known, but hypotheses include decreased 
levels of tumor necrosis factor (TNF), interleukin 
and inhibition of production and co-stimulation of 
CD8. Reports also suggest that thalidomide has a 
role in regulating helper cells (Th2). This would 
increase the production of Th2 cytokines IL4 and 
IL5 and inhibit the production of inflammatory 
lymphocytes (Th1) cytokine IFN and range in 
peripheral blood cells stimulated by antigens and 
mitogens (Pridgeon and Drake 2005). Laboratory 
studies performed with rabbit cornea show 
that thalidomide has antiangiogenic properties, 
possibly by blocking the action of potent 
angiogenic factors such as fibroblast growth factor 
(bFGF) and vascular endothelial growth factor 
(VEGF). In vitro studies have suggested that the 
inhibitory effect of angiogenesis is caused by 
certain metabolites formed in vivo rather than the 
parent compound. Another possibility suggests 
that inhibition of TNF-α may also be responsible 
for inhibiting angiogenesis, since TNF-α has 
a positive effect on angiogenesis (Kumar and 
Chhibber 2011).
CONCLUSIONS
1) Standardization of a sponge-induced angioge-
nesis in mice quantitated by comparison between 
hemoglobin content in serum and in sponge.
2) Sponge-induced angiogenesis can be suppressed 
by thalidomide.
RESUMO
No adulto, a angiogênese é restrita a poucas condições 
fisiológicas. Ao contrário, a angiogênese descontrolada 
frequentemente está associada a patologias dependentes 
de angiogênese. Vários modelos animais foram descritos 
para ajudar na análise quantitativa da angiogênese in vivo 
e caracterizar moléculas pró e antiangiogênicas. Porém, 
ainda é necessário estabelecer um método quantitativo, 
reproduzível e específico para estudar os fatores pró 
e antiangiogênicos. Os objetivos deste trabalho foram 
padronizar um método para estudar angiogênese e investigar 
os efeitos da talidomida na angiogênese. Esponjas de 0,5 x 
0,5 x 0,5 cm foram implantadas no dorso de camundongos 
controles e tratados (talidomida 200 mg/K/dia, por 
gavagem). Após sete dias, as esponjas foram retiradas. 
Avaliou-se a quantidade de hemoglobina na esponja 
e na circulação. A razão obtida entre esses valores foi 
testada por meio do teste não paramétrico Mann-Whitney. 
Os resultados mostraram que a angiogênese induzida pela 
esponja e quantificada por meio da razão hemoglobina 
esponja/circulação é um modelo útil para estudos in vivo de 
angiogênese. Além disso, observou-se que a angiogênese 
induzida pela esponja diminui na presença de talidomida, 
corroborando para a validação do método padronizado.
Palavras-chaves: modelo de angiogênese, avaliação de 
hemoglobina, implante de esponja, talidomida.
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